
Overview
Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). 1
Reference:
- Fendrix Summary of Product Characteristics. Available from:https://www.medicines.ie/medicines/fendrix-suspension-for-injection-32141/ Last accessed - June 2019
Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Fendrix is a registered trademark of the GlaxoSmithKline group of companies